Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503515 · ClinicalTrials.gov registry record · Phase 3
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 292
- Enrollment target
NCT01503515 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 292 participants.
The verdict
NCT01503515, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 292 participants
- Enrollment target
Study Summary
This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Fluconazole
- DRUG Voriconazole
- DRUG Caspofungin Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 292 participants |
| Start Date | 2013-03-21 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01503515
The ClinicalTrials.gov registry entry for NCT01503515 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 292 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01503515 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01503515 about?
NCT01503515 is a clinical study titled "Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant". This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in ...
What is the current status of trial NCT01503515?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 292 participants. The study started on 2013-03-21. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT01503515?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Fluconazole (DRUG), Voriconazole (DRUG), Caspofungin Acetate (DRUG).
Who is sponsoring clinical trial NCT01503515?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.